LINE OF CREDIT AGREEMENT FOR THE ACQUISITION OF EQUIPMENT AND LEASEHOLD IMPROVEMENTS ($1,250,000.00 Line)Line of Credit Agreement • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
We, Boston Private Bank & Trust Company (hereinafter “Lender”) are pleased to advise Curis, Inc. (the “Borrower”) that Lender has established a line of credit of up to One Million Two Hundred Fifty Thousand ($1,250,000.00) Dollars (subject to limitations contained herein) (hereinafter the “Credit Limit”) for Borrower to be used exclusively for the purchase of equipment, leasehold improvements and partial soft costs; subject to Lender’s periodic review. This line of credit will be subject to the following terms and conditions:
COMMON STOCK PURCHASE AND REGISTRATION RIGHTS AGREEMENTCommon Stock Purchase and Registration Rights Agreement • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances) • Delaware
THIS COMMON STOCK PURCHASE AND REGISTRATION RIGHTS AGREEMENT (this “Agreement”) dated as of January 9, 2004 is between Curis, Inc., a Delaware corporation (the “Company”), and Wyeth, acting through its Wyeth Pharmaceuticals division, a Delaware corporation (the “Purchaser”).
SECURED NON-REVOLVING TIME NOTESecured Non-Revolving Time Note • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances)
Unless the entire principal balance hereunder is converted to a term note in accordance with the Agreement for value received, on January 20, 2005, the undersigned, Curis, Inc. (the “Borrower”) promises to pay to Boston Private Bank & Trust Company (the “Bank”), or order, the principal sum of One Million Two Hundred Fifty Thousand ($1,250,000.00) Dollars, or if less, such amount as may be the aggregate unpaid principal amount of all Advances made by the Bank to the Borrower pursuant to a Line of Credit Agreement for the Acquisition of Equipment and Leasehold Improvements between the Borrower and the Bank of even date (the “Agreement”), together with interest (as provided below) on the aggregate unpaid principal balance from time to time outstanding on the first day of each calendar month, commencing on the first day of the first month next succeeding the date hereof, at a fluctuating interest rate per annum equal to the Bank’s Base Rate in effect from time to time plus one (1.0%) perce
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AMENDED AND RESTATED AGREEMENT AMONG THE JOHNS HOPKINS UNIVERSITY THE UNIVERSITY OF WASHINGTON CURIS, INC. JHU REF. NO.: 9765Amended and Restated Agreement • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Effective as of June 1, 2003 (“Effective Date”), The Johns Hopkins University, a body having corporate powers under the laws of the State of Maryland and an address at 3400 N. Charles St., Baltimore, Maryland, 21218- 2695 (“JOHNS HOPKINS”), the University of Washington (the “UNIVERSITY OF WASHINGTON”), a body having corporate powers under the laws of the State of Washington, and Curis Inc., formerly Ontogeny Inc., a Delaware corporation having a principal place of business at 61 Moulton Street, Cambridge, MA 02138 (“CURIS”), agree as follows:
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. AGREEMENTLicense Agreement • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances) • California
This License Agreement (this “Agreement”), effective as of December 4, 2002 (“Effective Date”), is made by and between Curis Inc., a Delaware corporation (“Curis”), having a place of business at 601 Moulton Street, Cambridge, Massachusetts 02138-1118, and Amylin Pharmaceuticals, Inc., a Delaware corporation (“Amylin”), having a place of business at 9373 Towne Centre Drive, Suite 250, San Diego, California 92121.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. COLLABORATION, RESEARCH AND LICENSE AGREEMENT BY AND BETWEEN WYETH acting through its WYETH PHARMACEUTICALS DIVISION AND CURIS...Collaboration, Research and License Agreement • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances) • New York
THIS AGREEMENT, dated as of January 12, 2004 (the “Signature Date”), between Wyeth, a Delaware corporation, acting through its Wyeth Pharmaceuticals Division, with a place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426 (“Wyeth”), and Curis Incorporated, a Delaware corporation having its principal offices at 61 Moulton Street, Cambridge, Massachusetts 02138. Wyeth and Curis may each be referred to herein individually as a “Party” and collectively as the “Parties”.
Amendment to Employment Agreement (“Amendment”)Employment Agreement • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances)
This Amendment to the Employment Agreement (“Agreement”), dated August 1, 2002, between Curis, Inc. (“Curis”) and Christopher U. Missling (“Employee”), is made as of the 1st day of January, 2004 (the “Effective Date”).
BOSTON PRIVATE BANK & TRUST COMPANY SECURITY AGREEMENT (SPECIFIC EQUIPMENT)Security Agreement • March 1st, 2004 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
Curis, Inc., a Delaware corporation with a principal place of business at 61 Moulton Street, Cambridge, Massachusetts 02138 and locations at 25 and 45 Moulton Street (hereinafter called “Borrower”), hereby grants to Boston Private Bank & Trust Company, a Massachusetts trust company with a principal place of business at Ten Post Office Square, Boston, Massachusetts 02109 (hereinafter called “Bank”), to secure the payment of $1,250,000.00 as provided in the Borrower’s Line of Credit Agreement for the Acquisition of Equipment and Leasehold Improvements, as amended from time to time, and all Notes executed pursuant thereto and all obligations of Borrower hereunder and thereunder (all hereinafter called the “Obligations”), a security interest in the following personal property of Borrower and any and all additions, substitutions, accessions and proceeds thereto or thereof including all insurance proceeds (all of the same being hereinafter called the “Collateral”):
